OncoMatch/Clinical Trials/NCT06420076
Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells
Is NCT06420076 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies CD5/CD7 CAR-T for t cell lymphoma.
Treatment: CD5/CD7 CAR-T — Chimeric antigen receptor (CAR)-modified T cells targeted against CD19 have demonstrated unprecedented successes in treating patients with hematopoietic and lymphoid malignancies. Besides CD19, many other molecules such as CD22, CD30,BCMA,CD123, etc. may be the potential to develop the corresponding CAR-T cells to treat patients whose tumors express those markers. In this study, investigators will evaluate the safety and efficacy of Sequential CAR-T Cells Targeting CD5/CD7 in patients with patients with relapsed or refractory T-ALL/LBL/ETP-ALL. The primary goal is safety assessment including cytokine storm response and any other adverse effects. In addition, disease status after treatment will also be evaluated.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD7 overexpression (≥70% by flow cytometry or immunohistochemistry)
Leukemic blast cells express CD7/CD5 (CD7 OR CD5 positive by flow cytometry or immunohistochemistry ≥70%)
Required: CD5 overexpression (≥70% by flow cytometry or immunohistochemistry)
Leukemic blast cells express CD7/CD5 (CD7 OR CD5 positive by flow cytometry or immunohistochemistry ≥70%)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Lab requirements
Blood counts
HGB≥70g/L (can be transfused)
Liver function
Total bilirubin does not exceed 3 times the upper limit of normal value, and AST and ALT do not exceed 5 times the upper limit of normal value.
Cardiac function
No atrial fibrillation; no myocardial infarction within the past 12 months; no prolonged QT syndrome or secondary QT prolongation; no clinically significant pericardial effusion; no cardiac insufficiency NYHA III or IV
HGB≥70g/L (can be transfused); Total bilirubin does not exceed 3 times the upper limit of normal value, and AST and ALT do not exceed 5 times the upper limit of normal value. One of the following cardiac issues: atrial fibrillation; myocardial infarction within the past 12 months; prolonged QT syndrome or secondary QT prolongation; clinically significant pericardial effusion; cardiac insufficiency NYHA (New York Heart Association) III or IV
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06420076 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require CD7?
Yes, CD7 overexpression is a required biomarker for enrollment.
Does this trial require CD5?
Yes, CD5 overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 90 years or younger and at least 2 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify